Left: Tony Budianto Bee, Head of Sales- Asia Region (excl. China) Bioprocess Solutions at Sartorius. Right: Pei-Jiun Chen, CEO and President of Mycenax.
Taipei, Taiwan, Mar 7, 2025
Mycenax (TWO:4726) and Sartorius have announced a strategic partnership to create comprehensive biopharmaceutical manufacturing solutions. This collaboration will combine the core strengths of both companies, enhance service capabilities, and expand their global market impact, providing customers with more efficient, flexible, and complete CDMO services.
Mycenax is Taiwan's only company 100% dedicated to biopharmaceutical CDMO services with over 20 years of professional experience, having successfully executed more than 150 protein drug process development and GMP projects worldwide. Mycenax is renowned for its highly flexible technical services, specializing in tailoring customized process solutions based on the unique characteristics of different protein drugs.
Sartorius, headquartered in Germany, is a globally recognized supplier of biopharmaceutical manufacturing equipment and materials. Their CHO cell line platform has successfully supported the market launch of seven new drugs and biosimilars worldwide, providing each drug with a high-quality, high-performance cell line as a production foundation from the early stages of development.
Through this powerful alliance, Mycenax will further expand its service scope. In addition to its existing high-efficiency cell line platform, Mycenax will seamlessly support global clients using Sartorius's CHO cells, completing subsequent process development and GMP production. This will provide customers with a complete one-stop service from raw materials to large-scale manufacturing and sterile filling, accelerating the progress of protein drugs into clinical trials and the market.
This collaboration is not only an integration of technology and resources but also a demonstration of both parties' shared commitment to service excellence, innovation, and sustainable development. Mycenax and Sartorius will jointly drive the development of the biotechnology and pharmaceutical industry, actively respond to global health needs, and create greater value in the biopharmaceutical field.
About Sartorius
Sartorius is a global lead supplier in the field of Biopharma Industry, specializing in providing high-quality solutions for the life sciences and biomanufacturing process. Founded in 1870 with over 150 years of history in Göttingen, Germany.
Sartorius focus on enabling the development and production of innovative medicines and vaccines by offering wide range of products- including cell line, cell culture mdium, bioreactor, upstream and downstream solutions, committed to drive sustainable growth and advancing scientific discovery by providing cutting-edge technology and expertise to improve health and well-being worldwide.
About Mycenax
Mycenax takes the CDMO brand positioning of "big D and medium M" with "Innovative development abilities (D) and Adequate manufacturing capacity (M)" to provides one-stop services for the development and manufacture of traditional biologics and novel biological drugs. At its core, Mycenax is committed to the development and production of biological drugs, from the R&D phase to cGMP manufacturing plants to drug commercialization. Mycenax, as an international CDMO company, continuously invests in product development innovations and technology platform optimizations in order to provide customers with comprehensive and streamlined CDMO services. Mycenax Biotech currently has a capital of 2.06 billion NTD.
Stock code: Mycenax Biotech (4726).
Company website: http://www.mycenax.com
Press Contact:
Liru Yeh
Email: liru.yeh@mycenax.com
Left: Tony Budianto Bee, Head of Sales- Asia Region (excl. China) Bioprocess Solutions at Sartorius. Right: Pei-Jiun Chen, CEO and President of Mycenax.
Taipei, Taiwan, Mar 7, 2025
Mycenax (TWO:4726) and Sartorius have announced a strategic partnership to create comprehensive biopharmaceutical manufacturing solutions. This collaboration will combine the core strengths of both companies, enhance service capabilities, and expand their global market impact, providing customers with more efficient, flexible, and complete CDMO services.
Mycenax is Taiwan's only company 100% dedicated to biopharmaceutical CDMO services with over 20 years of professional experience, having successfully executed more than 150 protein drug process development and GMP projects worldwide. Mycenax is renowned for its highly flexible technical services, specializing in tailoring customized process solutions based on the unique characteristics of different protein drugs.
Sartorius, headquartered in Germany, is a globally recognized supplier of biopharmaceutical manufacturing equipment and materials. Their CHO cell line platform has successfully supported the market launch of seven new drugs and biosimilars worldwide, providing each drug with a high-quality, high-performance cell line as a production foundation from the early stages of development.
Through this powerful alliance, Mycenax will further expand its service scope. In addition to its existing high-efficiency cell line platform, Mycenax will seamlessly support global clients using Sartorius's CHO cells, completing subsequent process development and GMP production. This will provide customers with a complete one-stop service from raw materials to large-scale manufacturing and sterile filling, accelerating the progress of protein drugs into clinical trials and the market.
This collaboration is not only an integration of technology and resources but also a demonstration of both parties' shared commitment to service excellence, innovation, and sustainable development. Mycenax and Sartorius will jointly drive the development of the biotechnology and pharmaceutical industry, actively respond to global health needs, and create greater value in the biopharmaceutical field.
About Sartorius
Sartorius is a global lead supplier in the field of Biopharma Industry, specializing in providing high-quality solutions for the life sciences and biomanufacturing process. Founded in 1870 with over 150 years of history in Göttingen, Germany.
Sartorius focus on enabling the development and production of innovative medicines and vaccines by offering wide range of products- including cell line, cell culture mdium, bioreactor, upstream and downstream solutions, committed to drive sustainable growth and advancing scientific discovery by providing cutting-edge technology and expertise to improve health and well-being worldwide.
About Mycenax
Mycenax takes the CDMO brand positioning of "big D and medium M" with "Innovative development abilities (D) and Adequate manufacturing capacity (M)" to provides one-stop services for the development and manufacture of traditional biologics and novel biological drugs. At its core, Mycenax is committed to the development and production of biological drugs, from the R&D phase to cGMP manufacturing plants to drug commercialization. Mycenax, as an international CDMO company, continuously invests in product development innovations and technology platform optimizations in order to provide customers with comprehensive and streamlined CDMO services. Mycenax Biotech currently has a capital of 2.06 billion NTD.
Stock code: Mycenax Biotech (4726).
Company website: http://www.mycenax.com
Press Contact:
Liru Yeh
Email: liru.yeh@mycenax.com